GlassScriptPhysician profile
Mary Katherine Busch
NPI 1821787300
$2,042.61
in general payments reported to CMS, 2019-2025
23 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $568 · 2024: $990 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.66 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $234.77 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $218.35 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $193.72 | 2023-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $160.19 | 2023-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $107.81 | 2023-2025 | |
| Astellas Pharma US INC | $105.58 | 2024-2025 | Veozah |
| Abbott Laboratories | $96.11 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.14 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $74.85 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $72.01 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $63.15 | 2023-2024 | Gvoke Hypopen |
| Gilead Sciences, INC. | $36.97 | 2025 | Yeztugo |
| Bayer Healthcare Pharmaceuticals INC. | $30.94 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $30.26 | 2023 | Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $24.30 | 2024 | Xtampza |
| Almatica Pharma LLC | $22.97 | 2023 | Loreev Xr |
| Sumitomo Pharma America, INC. | $22.83 | 2023 | Gemtesa |
| Amneal Pharmaceuticals LLC | $20.73 | 2024 | Unithroid |
| Eisai INC. | $17.12 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.36 | 2024 | |
| Merck Sharp & Dohme LLC | $14.26 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Aimmune Therapeutics, INC. | $13.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Busch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.